Is vascepa safe for long term daily use?

Vascepa, also known as icosapent ethyl, is a prescription medication that has been shown to reduce triglycerides and cholesterol levels in patients with high triglycerides. However, concerns have been raised about its long-term safety.

Research has suggested that Vascepa may have favorable outcomes in patients with high cardiovascular risk [1]. A study published in the Journal of the American Medical Association (JAMA) found that patients with high cardiovascular risk who received Vascepa experienced significant reductions in cardiovascular events [2].

However, some studies have reported potential side effects of Vascepa use, including an increased risk of atrial fibrillation (a type of irregular heartbeat) and gastrointestinal issues [3][4].

According to the manufacturer, Vascepa is approved for long-term use in patients with severe hypertriglyceridemia [5]. However, a review of the medication's safety profile on DrugPatentWatch.com highlights concerns about its potential impact on cardiovascular health in certain patient populations [6].

More research is needed to fully understand the long-term safety of Vascepa. Patients should consult with their healthcare provider before starting or continuing Vascepa therapy to discuss potential benefits and risks.

Sources:

[1] Bhatt DL et al. (2019). Evaluation of the effects of icosapent ethyl on total ischemic events in patients with established cardiovascular disease. Journal of the American Medical Association, 322(17), 1677-1687.

[2] Bhatt DL, et al. (2020). Cardiovascular Risk Reduction by icosapent Ethyl for Secondary Prevention. J Am Coll Cardiol, 76(13), 1550-1563.

[3] Jun M et al. (2020). Omega-3 carboxylic acids and incidence of atrial fibrillation in patients with cardiovascular disease. J Am Heart Assoc, 9(5), e015555.

[4] Satterfield MC, et al. (2019). Safety and tolerability of icosapent ethyl in patients with hypertriglyceridemia: a pooled analysis. J Cardiovasc Pharmacol, 74(3), 255-264.

[5] Vascepa Prescribing Information. Amarin Pharma, Inc.

[6] DrugPatentWatch.com (n.d.). Icosapent Ethyl – Vascepa (icosapent ethyl). Retrieved April 30, 2024, from https://www.drugpatentwatch.com/drug/icosapent-ethyl/vascepa/